CUSTOMER SERVICE  |  814.355.1030  |  Toll Free: 800.342.3595  |  M-F: 8am-4pm EST/EDT

Anti-ganglioside GM1 (polyclonal antibody)

CATALOG # 1954


  • Catalog #:1954
  • Scientific Name:Anti-ganglioside GM1 (polyclonal antibody)
  • Common Name:Polyclonal antibody to GM1, isotype IgG/IgM
  • SDS:View Safety Data Sheet
  • Data Sheet:View Data Sheet
  • Unit:100 µl
  • Solvent:none
  • Source:rabbit
  • Purity:serum, not purified
  • Analytical Methods:ELISA, TLC immunoblotting
  • Natural Source:rabbit
  • Solubility:water
  • Physical Appearance:liquid
  • Storage:-20°C
  • Dry Ice:Yes
  • Hazardous:No


Contact for Product Availability

Application Notes:

Anti-ganglioside GM1 is very useful in the identification of ganglioside GM1 and in immunotargeting cells expressing GM1. Several gangliosides have been found to have an elevated expression in tumor cells. Many therapeutic treatments of tumor cells are being investigated using antibodies to target cells that express these elevated levels of gangliosides. GM1 stimulates neuronal sprouting and enhances the action of nerve growth factor (NGF) by directly and tightly associating with Trk, the high-affinity tyrosine kinase-type receptor for NGF. It is also the specific cell surface receptor for cholera toxin. Because gangliosides are very important in neuronal cells, autoantibodies against gangliosides or other glycosphingolipids can lead to many autoimmune neuropathies such as demyelinating polyneuropathy, Guillain-Barré syndrome, motor neuron disease3 and sensorymotor neuropathy. IgM anti-GM1 occurs frequently in the serum of patients with multifocal motor neuropathy.4

1. H. Yoshino, et al., Journal of Neurochemisty, Vol. 61 pp. 658, 1993
2. S. Kusunoki, et al., Neurology, Vol. 37 pp. 1795, 1987
3. H. Yoshino, et al., Journal of Neurochemistry, Vol. 59(5):1684, 1992
4. A. Pestronk, MD and R. Choksi, MS Neurology, Vol. 49:1289, 1997
Price $446.00

Others Also Bought

Catalog #:
Catalog #:
Catalog #: 1950
Unit: 100 µl

Customer Reviews

Average Rating
Sign up for news & updates! Sign up!
Please Wait... processing